# Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

> **NCT03324425** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor Breast Care Center** · enrollment: 5 (actual)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Simvastatin 80mg

## Key facts

- **NCT ID:** NCT03324425
- **Lead sponsor:** Baylor Breast Care Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-04
- **Primary completion:** 2028-12
- **Final completion:** 2030-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324425, "Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03324425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*